Neon Bloom announced the endowment of a program known as ‘cERI’ (cannabis Education & Research Initiative). The program encompasses the donation by Bazelet of federally legal cannabis genetics (genetically producing 0% THC) to DEA registered research entities, such as the National Center for the Development of Natural Products at the University of Mississippi and the broader qualified scientific community wishing to conduct, disseminate and support rigorous scientific research on the clinical effects of cannabis. The company’s genetics are patented, compliant with the Controlled Substances Act (CSA) and are now available to all to conduct research with their genetics.
Global scientific research on the Cannabis Sativa L. plant has been illegal because of the Controlled Substance Act (CSA). The CSA has created a decades-long pent-up demand for the scientific research of the cannabis plant by qualified research entities. In 2016, the DEA announced that it was amending its longstanding policies to allow additional parties to grow cannabis for clinical research purposes. Since that time, it amended its regulations in 2020 (which became effective in January 2021) to facilitate the cultivation of cannabis for research purposes and other licit purposes to enhance compliance with the Controlled Substances Act, including registering cultivators consistent with treaty obligations but has not legalized cannabis research. In fact, to date, the DEA has only acknowledged providing a MOA (Memorandum of Agreement) to just a handful of applicants to “work together to facilitate the production, storage, packaging, and distribution of cannabis.” Meanwhile, human health and the global scientific community standby helpless until now. “Our genetic library of non-GMO, patented Cannabis Sativa L. plants offers access to cannabinoids such as Cannabigerol (CBG) with no existing THC or CBD,” said Dr. Francisco Ward NBPAS-PM&R/PM, Chief Medical Officer for Bazelet, which makes us a prime candidate for research endeavors.
“Having been involved with the DEA regarding its amendment to facilitate the cultivation of cannabis for research purposes and other licit purposes to enhance compliance with the Controlled Substances Act, I recognize and appreciate the DEA’s unique implementation challenges. I am certain our patented cannabis plants and robust plant science program can immediately deliver value to their program, their researchers, and manufacturers. For decades worldwide, cannabis plants have been almost exclusively bred to yield higher and higher concentrations of Tetrahydrocannabinol (THC) which has fueled a multi-billion recreational and high THC medical cannabis industry. This breeding habit has caused the abandonment, if you will, of hundreds of compounds in the cannabis plant to the detriment of human health, scientific study, and federal law. We have developed an unprecedented plant genetic platform for the DEA that begins with registered, US plant patent approved Cannabis Sativa L. plants as its foundation. Our unique genetic program will allow DEA registered research entities to unlock untold scientific and human health outcomes by accessing a full array of cannabinoids and compounds found in the Cannabis Sativa L. plant, such as Cannabigerol (CBG). Our program allows the DEA, from here forward, the development of world-class cannabis genetics that began with registered, US patented cannabis genetics,” says Michael Elzufon, CEO of the Bazelet Health Systems.
“Through our cannabis Education & Research Initiative (cERI), we are opening our genetic library to DEA registered research entities, encouraging their rigorous scientific and medical research projects with federally legal cannabis products. With the DEA slow in issuing bulk manufacturer registrations, research projects remain on hold, and our patented, federally compliant cannabis genetics are an immediate solution,” said Dr. Ward. He added, “I look forward to collaborating with colleagues, scientists, DEA bulk manufacturer applicants and patients everywhere, to study, innovate and access the potential of this plant in the areas of neurodegenerative diseases, auto-immune diseases, vascular diseases, psychiatric diseases such as addiction, delusional states, and PTSD.”
For more information:
Bazelet
[email protected]
www.bazelet-n.com